|
On May 15, 2024, the FDA granted accelerated approved for idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic therapy, based on results from the Phase 2 TRANSCEND-FL trial. Read More
On May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra) for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or following platinum-based chemotherapy based on the DeLLphi-301 study. Read More
On May 29, 2024, the FDA granted accelerated approval to selpercatinib (Retevmo) to pediatric patients aged 2 years or older who have advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine refractory, if radioactive iodine is appropriate or locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or after previous systemic treatment or who have no satisfactory alternative options. Approval is based on the phase 1/2 LIBRETTO-121 study. Read More
On May 30, 2024, the FDA approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi) based on the TRANSCEND-MCL trial. Read More
| 
